Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Invested Capital (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Invested Capital for 12 consecutive years, with $41.6 million as the latest value for Q1 2026.

  • For Q1 2026, Invested Capital fell 80.65% year-over-year to $41.6 million; the TTM value through Mar 2026 reached $41.6 million, down 80.65%, while the annual FY2025 figure was $64.6 million, 78.47% down from the prior year.
  • Invested Capital hit $41.6 million in Q1 2026 for Syndax Pharmaceuticals, down from $64.6 million in the prior quarter.
  • Across five years, Invested Capital topped out at $554.2 million in Q4 2023 and bottomed at $41.6 million in Q1 2026.
  • Average Invested Capital over 5 years is $322.9 million, with a median of $366.4 million recorded in 2024.
  • Year-over-year, Invested Capital surged 66.59% in 2022 and then plummeted 80.65% in 2026.
  • Syndax Pharmaceuticals' Invested Capital stood at $467.4 million in 2022, then increased by 18.56% to $554.2 million in 2023, then tumbled by 45.82% to $300.2 million in 2024, then crashed by 78.47% to $64.6 million in 2025, then crashed by 35.6% to $41.6 million in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $41.6 million, $64.6 million, and $115.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.